Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers
Completed · Phase 1 · Has a placebo group
Conditions studied: Healthy Volunteers
In brief
The main purpose of this study is to evaluate the effect of single oral therapeutic and supratherapeutic doses of AKB-6548 on the QT interval.
Key facts
- Study ID
- NCT02062203
- Run by
- Akebia Therapeutics
- People needed
- 50
- Starts
- 2014-01-01
- Expected to finish
- 2014-04-01
- Last updated by the study team
- 2018-11-14
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Study site — Evansville, Indiana, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.